Second and third line treatment options for Helicobacter pylori eradication

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Helicobacter pylori is a prevalent bacterium causing significant disease burden globally.
• Increasing primary antibiotic resistance rates are leading to declining eradication success.
• Clinicians face challenges with recurrent H. pylori infections and require knowledge of salvage therapies.

Purpose of the Study:

• To discuss factors contributing to H. pylori treatment failure.
• To review established and investigated second- and third-line treatment strategies.
• To guide clinicians in selecting appropriate salvage therapy for H. pylori infections.

Main Methods:

• Review of literature on H. pylori treatment failure.
• Analysis of factors contributing to eradication failure.
• Evaluation of second- and third-line treatment options, including empiric and susceptibility-guided therapies.

Main Results:

• Established empiric second-line options include bismuth-based quadruple therapy and levofloxacin-based triple therapy.
• Antibiotic susceptibility testing is recommended before third-line treatment.
• When testing is unavailable, third-line options include rifabutin, rifaximin, and sitafloxacin-based therapies.

Conclusions:

• Rising antibiotic resistance complicates H. pylori eradication.
• Effective salvage therapies are crucial for managing treatment failures.
• Knowledge of second- and third-line strategies, including antibiotic testing, is essential for successful H. pylori treatment.